Brokerage Firm Rating Update on ResMed (RMD)

ResMed (RMD) : Zacks Investment Research ranks ResMed (RMD) as 3, which is a Hold recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. Not everyone is convinced about the stocks future, hence, the stock receives 1 Sell recommendation. 3 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 9 research analysts is 3.39, which indicates as a Hold.

ResMed (RMD) : The highest level ResMed (RMD) is projected to reach is $74 for the short term and the lowest estimate is at $50. The consolidated price target from 7 rating analysts who initiate coverage on the stock is $61.53 and the possibility the share price can swing is $8.23.


Company shares have received an average consensus rating of Hold for the current week Also, Jefferies downgrades its view on ResMed (NYSE:RMD) according to the research report released by the firm to its investors. The shares have now been rated Underperform by the stock experts at the ratings house. Earlier, the shares had a rating of Hold. Jefferies lowers the price target from $60 per share to $58 per share on ResMed . The rating by the firm was issued on August 23, 2016.

ResMed (NYSE:RMD): The stock opened at $67.43 and touched an intraday high of $68.4 on Wednesday. During the day, the stock corrected to an intraday low of $67.35, however, the bulls stepped in and pushed the price higher to close in the green at $67.6 with a gain of 0.19% for the day. The total traded volume for the day was 737,187. The stock had closed at $67.47 in the previous trading session.

ResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.